financetom
Business
financetom
/
Business
/
Form 8.3 - Greencore Group PLC
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - Greencore Group PLC
Sep 24, 2025 3:28 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Qube Research & Technologies Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Greencore Group PLC ( GNCGF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

23-09-2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

Bakkavor Group PLC

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

6,400,715

1.44

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

TOTAL:

6,400,715

1.44

0

0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

0

Details, including nature of the rights concerned and relevant percentages:

0

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (GBp)

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. call option

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of securities

Exercise price per unit (GBp)

1p ordinary

equity swap

decreasing a long position

731

231.50

1p ordinary

equity swap

decreasing a long position

658

233.25

1p ordinary

equity swap

decreasing a long position

517

234.00

1p ordinary

equity swap

decreasing a long position

1422

235.75

1p ordinary

equity swap

decreasing a long position

617

236.00

1p ordinary

equity swap

decreasing a long position

853

236.50

1p ordinary

equity swap

decreasing a long position

1019

236.75

1p ordinary

equity swap

decreasing a long position

1725

237.00

1p ordinary

equity swap

decreasing a long position

1190

237.25

1p ordinary

equity swap

decreasing a long position

1067

237.50

1p ordinary

equity swap

decreasing a long position

552

237.75

1p ordinary

equity swap

decreasing a long position

798

238.00

1p ordinary

equity swap

decreasing a long position

503

239.50

1p ordinary

equity swap

increasing a long position

248

230.50

1p ordinary

equity swap

increasing a long position

687

231.00

1p ordinary

equity swap

increasing a long position

1184

232.00

1p ordinary

equity swap

increasing a long position

2953

232.50

1p ordinary

equity swap

increasing a long position

334

233.50

1p ordinary

equity swap

increasing a long position

952

234.00

1p ordinary

equity swap

increasing a long position

277

234.50

1p ordinary

equity swap

increasing a long position

541

236.00

1p ordinary

equity swap

increasing a long position

115

237.00

1p ordinary

equity swap

increasing a long position

1642

237.50

1p ordinary

equity swap

increasing a long position

3212

238.00

1p ordinary

equity swap

increasing a short position

63

229.50

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBp)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit
(GBp)

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

0

0

0

0

 

0

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

0

 

0

0

0

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(c) Attachments

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

6,400,715

1.44

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

TOTAL:

6,400,715

1.44

0

0.00

0

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

6,400,715

1.44

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

TOTAL:

6,400,715

1.44

0

0.00

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Qube Research & Technologies LTD

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PharmaTher's Sairiyo Therapeutics Gets OK to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
PharmaTher's Sairiyo Therapeutics Gets OK to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
Aug 19, 2024
08:04 AM EDT, 08/19/2024 (MT Newswires) -- PharmaTher Holdings Ltd. ( PHRRF ) , a specialty pharmaceutical company, announced Monday Sairiyo Therapeutics Inc., a company that is 49% owned by PharmaTher ( PHRRF ) and 51% owned by PharmaDrug Inc. ( LMLLF ) , has received approval by the Australian Human Research Ethics Committee to initiate a first-in-human Phase 1...
Laramide Resources Says Australian Drilling Proceeding as Planned
Laramide Resources Says Australian Drilling Proceeding as Planned
Aug 19, 2024
08:05 AM EDT, 08/19/2024 (MT Newswires) -- Laramide Resources ( LMRXF ) , a uranium mine development and exploration company with assets in the United States and Australia, on Monday provided an update on its drilling activities at the Westmoreland Uranium Project in Queensland, Australia. This season's exploration drilling campaign is comprised of up to 12,000 metres of diamond and...
Tonix Pharmaceuticals Holding's Q2 Loss Narrows, Revenue Rises
Tonix Pharmaceuticals Holding's Q2 Loss Narrows, Revenue Rises
Aug 19, 2024
08:01 AM EDT, 08/19/2024 (MT Newswires) -- Tonix Pharmaceuticals Holding ( TNXP ) reported a Q2 loss Monday of $19.28 per diluted share, narrowing from a loss of $49.23 a year earlier. Three analysts polled by Capital IQ expected a loss of $3.27. Revenue for the quarter ended June 30 was $2.21 million, compared with no revenue a year earlier....
Tiziana Life Sciences Names Ivor Elrifi as CEO
Tiziana Life Sciences Names Ivor Elrifi as CEO
Aug 19, 2024
08:05 AM EDT, 08/19/2024 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Monday it has named Ivor Elrifi as chief executive officer, effective immediately. He succeeds Gabriele Cerrone, who served as chief executive and will remain as executive chairman of the board. Elrifi previously served as global head of the patent group at Cooley and global head of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved